Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M400549200 on May 5, 2004

J. Biol. Chem., Vol. 279, Issue 29, 30369-30374, July 16, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/29/30369    most recent
M400549200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schulze, P. C.
Right arrow Articles by Lee, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulze, P. C.
Right arrow Articles by Lee, R. T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-interacting Protein*

P. Christian Schulze{ddagger}, Jun Yoshioka{ddagger}, Tomosaburo Takahashi{ddagger}, Zhiheng He§, George L. King§, and Richard T. Lee{ddagger}

From the {ddagger}Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School and §Vascular Cell Biology & Complications, Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts 02139

Received for publication, January 18, 2004 , and in revised form, March 23, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Increased intracellular reactive oxygen species (ROS) contribute to vascular disease and pro-atherosclerotic effects of diabetes mellitus may be mediated by oxidative stress. Several ROS-scavenging systems tightly control cellular redox balance; however, their role in hyperglycemia-induced oxidative stress is unclear. A ubiquitous antioxidative mechanism for regulating cellular redox balance is thioredoxin, a highly conserved thiol reductase that interacts with an endogenous inhibitor, thioredoxin-interacting protein (Txnip). Here we show that hyperglycemia inhibits thioredoxin ROS-scavenging function through p38 MAPK-mediated induction of Txnip. Overexpression of Txnip increased oxidative stress, while Txnip gene silencing restored thioredoxin activity in hyperglycemia. Diabetic animals exhibited increased vascular expression of Txnip and reduced thioredoxin activity, which normalized with insulin treatment. These results provide evidence for the impairment of a major ROS-scavenging system in hyperglycemia. These studies implicate reduced thioredoxin activity through interaction with Txnip as an important mechanism for vascular oxidative stress in diabetes mellitus.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Vascular complications such as coronary disease, peripheral artery disease, and stroke are major determinants of morbidity and mortality of patients with diabetes mellitus (1). Atherosclerosis accelerates in the diabetic state (1–3). Increased formation of reactive oxygen species (ROS)1 contributes to endothelial dysfunction, vessel wall thickening, and lesion formation, thereby playing a crucial role in the progressive deterioration of vascular function and structure (4, 5). While low levels of ROS participate in important cellular signaling mechanisms (6), increased formation of ROS results in cytotoxic oxidative stress (5). Several antioxidative systems tightly regulate cellular redox balance and control formation and reduction of ROS (5, 7, 8). Previously, oxidative stress in diabetes mellitus has been linked to enhanced production of superoxide anion by mitochondria (9) and through protein kinase C-dependent activation of membranous NADPH oxidase (10). However, the intracellular redox balance is maintained by ROS-scavenging systems, and the two major intracellular thiol-reducing mechanisms are the interacting glutathione and thioredoxin systems (8, 11, 12). Thioredoxin reduces ROS through reversible oxidation of thioredoxin at two cysteine residues (Cys-32 and Cys-35); thioredoxin is then reduced by thioredoxin reductase and NAPDH (11). Thioredoxin-interacting protein (Txnip), the endogenous inhibitor of thioredoxin also known as vitamin D3 up-regulated protein-1 (VDUP-1) (13, 14) or thioredoxin-binding protein-2 (TBP-2) (15), inhibits thioredoxin antioxidative function by binding to its redox-active cysteine residues (15, 16).

We show here the inhibition of the thioredoxin ROS-scavenging system through induction of Txnip in hyperglycemia. In contrast to previous reports describing an increased formation of reactive oxygen species in hyperglycemia, our study demonstrates the functional inhibition of a major cytoplasmic antioxidant system in hyperglycemia. Moreover, the inhibition of thioredoxin function in hyperglycemia through increased interaction with its inhibitor Txnip forms the molecular basis of increased levels of the freely diffusible molecule hydrogen peroxide contributing to oxidative stress. This molecular interaction might play a central role in increasing levels of reactive oxygen species by reduced flow through the enzymatic pathways of ROS scavenging.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—Human aortic smooth muscle cells (SMCs) were isolated from surgical specimens and cultured in Dulbecco's modified essential medium with 10% fetal calf serum. Cells were starved for 48 h in insulin-transferrin medium prior to experiments. Stimulation experiments were performed using glucose (Sigma), insulin (100 nM, Sigma), insulin-like growth factor-1 (IGF-1) (100 ng/ml, Upstate Biotechnology), PDGF-BB (4 ng/ml, Upstate Biotechnology). The following inhibitors were used: wortmannin (100 nM, Sigma), PD169316 (100 nM, Calbiochem), U0126 (10 µM, Calbiochem), GF109203X (5 µM, Calbiochem), and pertussis toxin (500 ng/ml, Sigma).

Northern and Western Analyses—For the detection of mRNA transcripts by Northern analysis, specific cDNA probes were synthesized using the following oligonucleotides: thioredoxin, 5'-AGCAGCCAAGATGGTGAAGCAGA-3' and 5'-GCTCCAGAAAATTCACCCACC-3'; Txnip, 5'-TCTGCCAAAAAGGAGAAGAAAG-3' and 5'-GGCGTACATAAAGATAGGGCTG-3'. Total RNA was isolated and loaded to a 1% agarose formaldehyde gel. After transfer, the membranes were incubated with radioactive labeled probes, and specific binding was visualized with autoradiography. Western analysis was performed using a specific monoclonal anti-Txnip antibody that was raised against full-length human Txnip. Thioredoxin was detected by a monoclonal anti-thioredoxin antibody (Medical Biological Laboratories International). After incubation with horseradish peroxidase-conjugated secondary antibody, specific bands were visualized by enzymatic chemiluminescence reaction (PerkinElmer Life Sciences). Total Akt, phospho-Akt, total p38 MAPK, and phospho-p38 MAPK were detected using specific antibodies (Cell Signaling).

Real Time PCR—Txnip gene expression was analyzed by real time PCR (LightCycler, Roche Applied Science) using specific oligonucleotides: human Txnip, 5'-TGGTGGATGTCAATACCCCT-3' (sense) and 5'-ATTGGCAAGGTAAGTGTGGC-3' (antisense); human {beta}-tubulin, 5'-TCTGTTCGCTCAGGTCCTTT-3' (sense) and 5'-TTCATGATGCGATCAGGGTA-3' (antisense); rat Txnip, 5'-CAAGTTCGGCTTTGAGCTTC-3' (sense) and 5'-GCCATTGGCAAGGTAAGTGT-3' (antisense); rat {beta}-tubulin, 5'-CATCCAGGAGCTCTTCAAGC-3' (sense) and 5'-CGCCTTAGGCCTCTTCTTCT-3' (antisense); human thioredoxin, 5'-AGCAGCCAAGATGGTGAAGCAGA-3 (sense) and 5'-GCTCCAGAAAATTCACCCACC-3' (antisense); rat thioredoxin, 5'-GCTGATCGAGAGCAAGGAAG-3 (sense) and 5'-TCAAGGAACACCACATTGGA-3' (antisense).

Adenoviral Vectors for Gene Transfer—Adenoviral vectors for overexpression of TRX (AdTRX) and Txnip (AdTxnip) were used as described elsewhere (14).

Gene Silencing by Small Interfering RNA (RNAi)—Double-stranded RNAi (Qiagen) for selective silencing of Txnip (rACAGACUUCGGAGUACCUGdTT) was transfected into cells (FuGENE Reagent, Roche Applied Science). After transfection, cells were incubated with glucose for Txnip expression. Scrambled RNAi was used as control.

Measurement of Oxidative Stress—Cells were incubated with 2',7'-dichlorodihydrofluorecein diacetate (DCFDA) for 45 min, washed in phosphate-buffered saline, and fluorescence intensity measured using a fluorometer (PerkinElmer Life Science) at 595 nm. Tissue levels of ROS were detected on frozen sections by incubation with dihydroethidium bromide (DHE) for 30 min at 37 °C followed by fluorescence microscopy.

Thioredoxin Activity Assay—Thioredoxin activity was measured using the insulin disulfide reduction assay as described elsewhere (11). In brief, 50 µg of cellular protein extracts were incubated at 37 °C for 15 min with activation buffer to reduce thioredoxin. After addition of reaction buffer, the reaction was started with 5 µl of bovine thioredoxin reductase (American Diagnostica Inc., Greenwich, CT) or 5 µl of water to controls and samples incubated for 20 min at 37 °C. The reaction was terminated by adding 250 µl of stopping buffer followed by absorption measurement at 412 nm.

In Vivo Model of Diabetes Mellitus—Streptozotocin (STZ, 60 mg/kg) was injected intraperitoneally in adult Sprague-Dawley rats. The animals were either sacrificed 4 weeks after injection of STZ or treated with insulin (10 IU/kg/day, subcutaneously). Vehicle-injected animals served as controls. Vascular tissues were isolated from the aorta of the animals. All experimental procedures complied with the rules and regulations of the Committee on Ethics and Animal Research at the Joslin Diabetes Center.

Histology—Thioredoxin and Txnip were immunohistochemically detected by incubation with primary antibody (1:200) followed by incubation with biotinylated secondary antibody (1:200). Specific binding was visualized by diaminobenzoate.

Statistical Analysis—All in vitro experiments were performed at least three times and data are expressed as mean ± s.d. The data were analyzed by Student's t test. One-way analysis of variance with post hoc analysis was used for the analysis of data sets of more than two groups. p < 0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Induction of Txnip in Hyperglycemia Enhances Oxidative Stress—Since increased oxidative stress contributes to the development of vascular complications in diabetes, we investigated the regulation of thioredoxin antioxidative function in hyperglycemia. Human aortic SMCs incubated with increasing concentrations of glucose showed a concentration-dependent reduction of thioredoxin activity (25 mM glucose: –55 ± 19% versus base line, p < 0.01; Fig. 1A). Thioredoxin can be oxidized through interaction with hydrogen peroxide (11), which can be measured by the cell-permeable and redox-sensitive compound DCFDA (6). Incubation of SMCs with glucose increased intracellular levels of ROS as assessed by DCFDA fluorescence in a concentration-dependent matter (10 mM glucose: +40.2 ± 8.5%; p < 0.01 versus 5.6 mM glucose and 25 mM glucose: +76.3 ± 2.7%; p < 0.001 versus 5.6 mM glucose). Glucose incubation did not change the expression of thioredoxin mRNA or protein levels (Fig. 1B). However, incubation with glucose markedly induced expression of Txnip (18.6 ± 6.4-fold versus base line; p < 0.05; Fig. 1B) both in cells stimulated with 25 mM glucose after being cultured for 48 h with 5.6 mM glucose (340 ± 64%) and cells cultured in glucose-free medium (440 ± 112% versus base line; p < 0.05). Co-incubation with insulin had no effect on the regulation of Txnip suggesting that glucose directly and independently regulates Txnip expression (Fig. 1C). Co-immunoprecipitation studies showed that the hyperglycemia-induced increase in Txnip protein levels enhanced the thioredoxin/Txnip protein interaction (Fig. 1D). The induction of Txnip by glucose was also found in several primary and non-primary cells such as neonatal rat cardiomyocytes (17.0 ± 5.1-fold; p < 0.01), human endothelial cells (8.9 ± 2.3-fold; p < 0.01), HeLa cells (4.71 ± 2.6-fold; p < 0.05), SOL8 myoblasts (+24.0 ± 13.0-fold; p < 0.001) and NIH 3T3 fibroblasts (+9.6 ± 4.6-fold; p < 0.05; data not shown). Thus, glucose-mediated regulation of thioredoxin through Txnip appears to be a ubiquitous mechanism.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 1.
Hyperglycemia promotes the formation of ROS through induction of Txnip. A, glucose incubation results in a concentration-dependent decrease of thioredoxin (Trx) activity in vascular smooth muscle cells compared with controls (5.6 mM). B, Txnip expression is regulated by glucose in a time-dependent manner without significant differences in Trx expression. Txnip mRNA (top) increases as early as 1 h of incubation with glucose (25 mM). Txnip protein levels (bottom) increase after 2 h of incubation with glucose. C, the expression of Txnip mRNA is regulated by glucose independent from insulin (100 nM). Induction of Txnip expression by hyperglycemia (25 mM glucose) is detectable after 4 h of stimulation in the absence and in the presence of insulin. D, hyperglycemia enhances the interaction of Txnip with Trx. Cells were stimulated with glucose (25 mM) and total proteins extracted. Immunoprecipitation of Trx was performed using protein G-Sepharose beads coated with a monoclonal anti-Txnip antibody. Uncoated beads and beads coated with unspecific IgG served as controls. Lanes 1 and 2 show levels of Trx in total cell lysates, lanes 3 and 4 show negative controls, and lanes 5 and 6 show immunoprecipitated Trx. E, incubation with increasing concentrations of glucose induces levels of reactive oxygen species as detected by DCFDA fluorescence. Adenoviral gene transfer of Txnip increases levels of reactive oxygen species in hyperglycemia; this was inhibited by overexpression of Trx. Cells were infected with adenoviral vectors for overexpression of Txnip, Trx, or GFP alone (controls). After 48 h, cells were stimulated with glucose (10 and 25 mM). 45 min before the end of the experiments, 10 µM DCFDA was added to the medium. Cells were washed in Hank's balanced salt solution and fluorescence intensity measured on a fluorescence plate reader. Fluorescence intensity was background-corrected and expressed as percent increase compared with non-stimulated cells of each group (n = 26 per data point). F, gene silencing of Txnip reduces protein levels of Txnip. G, gene silencing of Txnip prevents the glucose-induced reduction of Trx activity. Cells were transfected with Txnip silencing or scrambled RNAi for 48 h before Trx activity was assessed (n = 12 per data point). H, cellular levels of ROS in hyperglycemia were also reduced by gene silencing of Txnip as compared with scrambled RNAi (n = 25 per data point). *, p < 0.05 compared with non-stimulated cells. **, p < 0.01 compared with non-stimulated cells. ***, p < 0.001 compared with non-stimulated cells. {dagger}, p < 0.05 versus scrambled RNAi.

 
Overexpression of Txnip using adenoviral gene transfer resulted in increased cellular levels of ROS at 10 mM glucose (+68.8 ± 32.9% versus AdGFP-infected cells; p < 0.01) and at 25 mM glucose (+95.8 ± 15.1% versus AdGFP-infected cells; p < 0.001). In contrast, overexpression of thioredoxin strongly inhibited the increase in ROS at both 10 and 25 mM glucose (Fig. 1E). These findings are consistent with previous reports showing the functional effects of adenoviral gene transfer of Txnip and thioredoxin (13, 14). Overexpression of Txnip results in increased protein levels of Txnip (>30-fold) and functional inhibition of thioredoxin activity by 61 ± 23%. In turn, adenoviral gene transfer of thioredoxin increases thioredoxin protein levels (>20-fold) and thioredoxin activity by 270 ± 40% (14). Txnip gene knockdown induced through post-transcriptional interference of specifically designed Txnip RNAi (Fig. 1F) inhibited the hyperglycemia-induced reduction of thioredoxin activity (96.6 ± 15.3% of base-line activity in cell transfected with Txnip RNAi versus 58.4 ± 19.3% in cells transfected with scrambled RNAi under 25 mM glucose; p < 0.05; Fig. 1G). Furthermore, gene knockdown of Txnip reduced the glucose-induced increase in oxidative stress by 27.4 ± 1.1% under 10 mM glucose and by 35.8 ± 9.8% under 25 mM glucose compared with controls (both p < 0.05 versus scrambled RNAi) without significant differences at base line (Fig. 1H). These findings support the specific inhibition of the thioredoxin antioxidative system in hyperglycemia through induction of Txnip, the endogenous inhibitor of thioredoxin function.

Induction of Txnip in Hyperglycemia Is Mediated by p38 MAPK—We next analyzed the underlying cellular signaling mechanisms that regulate glucose-induced expression of Txnip. Incubation of aortic SMCs with hyperglycemic concentrations of glucose (25 mM) resulted in a phosphorylation of p38 MAPK after 30 min that was prevented by preincubation with the p38 MAPK inhibitor PD169316 (Fig. 2A). In addition, inhibition of p38 MAPK abolished the glucose-induced expression of Txnip mRNA (Fig. 2B) and protein (Fig. 2C). Therefore, glucose-induced activation of p38 MAPK is required for the induction of Txnip expression.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 2.
Transcriptional Regulation of Txnip. A, incubation with D(+)-glucose (25 mM) induces activation of p38 MAPK. Inhibition of p38 MAPK blocks the glucose-induced expression of Txnip mRNA and protein. Incubation with L(+)-glucose (25 mM) has no effects on the expression of Txnip (B and C). D, PDGF-BB (4 ng/ml) induces phosphorylation of Akt that is inhibited in hyperglycemia (25 mM). E, activation of PI 3-kinase by PDGF-BB negatively regulates Txnip mRNA expression whereas the PI 3-kinase inhibitor wortmannin increases expression of Txnip. *, p < 0.01 compared with controls. **, p < 0.05 compared with glucose-stimulated cells.

 
Activation of PI 3-Kinase Suppresses Txnip—Further experiments revealed enhanced glucose-induced expression of Txnip in the presence of the PI 3-kinase inhibitor wortmannin (31.4 ± 19.9-fold versus 14.6 ± 5.6-fold in glucose-stimulated cells; p < 0.05). No effects were detectable after incubation with the ERK inhibitor U0126, Gi inhibition by pertussis toxin, or protein kinase C (PKC) inhibition by GF109203X (data not shown). PKC activation (phorbol myristate acetate, 100 nM), a central mediator of glucose-induced cellular signaling mechanisms (17), did not affect the expression of Txnip. As shown previously (18), incubation of SMCs with hyperglycemic levels of glucose reduced the PI 3-kinase-dependent phosphorylation status of Akt in response to stimulation with PDGF-BB (4 ng/ml) (Fig. 2D). Activation of PI 3-kinase through stimulation with PDGF-BB reduced glucose-induced expression of Txnip mRNA by 45.4 ± 16.4% (p < 0.01 versus non-stimulated cells) (Fig. 2E). Taken together, these findings indicate that the PI 3-kinase pathway inhibits Txnip expression, and its inhibition in hyperglycemia promotes the expression of Txnip.

Vascular Regulation of Txnip in Diabetes Mellitus in Vivo—We next investigated the functional regulation of the thioredoxin system in an animal model of diabetes mellitus in vivo. The diabetic state was induced in adult rats through intraperitoneal injection of STZ. First, we assessed increased formation of superoxide anion in vascular samples of animals with diabetes mellitus. Superoxide anion, an intermediate product of cellular redox scavenging pathways, can be detected on frozen tissue sections by the redox-sensitive compound DHE that is oxidized to a characteristic fluorescing and DNA-interacting product (19–21). Although superoxide is not directly scavenged by thioredoxin, which can efficiently scavenge hydrogen peroxide, increased vascular oxidative stress has been previously documented in diabetic animals with this method (21). DHE staining revealed increased levels of superoxide in vessels from diabetic animals compared with controls (Fig. 3A).



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 3.
Regulation of Trx function through Txnip in vivo. A, animals with STZ-induced diabetes mellitus exhibit increased vascular levels of superoxide anion as detected by nuclear DHE staining as compared with non-diabetic controls. B, reduced vascular thioredoxin activity in diabetic animals compared with controls normalizes under insulin treatment (n = 6 per group). Increased vascular expression of Txnip is detectable in diabetes mellitus that normalizes under insulin treatment. In contrast, no significant changes in Trx expression or protein levels were detectable (n = 9 per group). *, p < 0.05 compared with controls (C and D). E, immunostaining reveals increased immunoreactivity of Txnip in the vascular media of vessels of diabetic animals without differences in Trx immunoreactivity. Vascular tissues were isolated from the aorta of the animals.

 
Vascular thioredoxin activity was reduced in animals with diabetes mellitus compared with controls (26.7 ± 22.6 versus 79.0 ± 44.6 ng of thioredoxin per µg of total protein; p < 0.01 versus base line) but normalized under insulin treatment (59.3 ± 1.3 ng of thioredoxin per µg of total protein; p = 0.78 versus base line; Fig. 3B). Vascular expression of Txnip increased dramatically in diabetic animals (379.7 ± 123.5% of base-line expression; p < 0.001) without changes in the expression of thioredoxin (83.8 ± 41.9% of base-line expression; p = 0.83; Fig. 3C). Normalization of serum glucose by insulin treatment reduced Txnip expression to base-line levels (81.3 ± 13.9% of base line; p = 0.79). In addition, vascular Txnip protein levels increased in diabetes mellitus and normalized with insulin treatment (Fig. 3D). Immunohistochemical analysis of vascular sections showed strong immunoreactivity for Txnip in the media of aortas from diabetic animals with no changes in thioredoxin levels (Fig. 3E).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The thioredoxin system regulates cellular redox balance through the reversible oxidization of its redox-active cysteine residues (-Cys-Gly-Pro-Cys-) to form a disulfide bond that in turn is reduced by thioredoxin reductase and NADPH (11). Targeted deletion of thioredoxin causes early embryonic lethality (22). The thioredoxin system compensates for a lack of glutathione reductase in Drosophila melanogaster, emphasizing the role of this system as a central and highly conserved antioxidative cellular defense mechanism (23). In endothelial cells, S-nitrosylation at Cys-69 is required for the anti-apoptotic and redox regulatory function of thioredoxin (24). In addition, thioredoxin functions as a crucial mediator of redox-mediated transcriptional activation (25, 26). After nuclear translocation, thioredoxin can bind by reduction of its redox-active cysteine residues to the transcriptional activator Ref-1, which in turn increases the DNA binding activity of AP-1 and also activates ribonucleotide reductase, a key enzyme in DNA synthesis (25). As part of the cellular stress response, cells express and release a truncated thioredoxin isoform (10 kDa) through a non-typical secretion pathway (27). The truncated isoform has growth-inducing abilities and can act as a chemokine (27). However, it lacks the reducing capacity of full-length thioredoxin and does not participate in the regulation of ROS (28).

The endogenous thioredoxin inhibitor Txnip binds to the active site of thioredoxin and inhibits thioredoxin activity (15). Txnip competes with other thioredoxin-binding proteins such as apoptosis-signaling kinase-1 (ASK1) (16) and inhibits the thioredoxin-mediated degradation of ASK1 through ubiquitination (29), thereby sensitizing cells to apoptotic stimuli (13). In addition, Txnip prevents the nuclear translocation of thioredoxin (14) and regulates thioredoxin-dependent transcriptional mechanisms. Txnip has been described as an intracellular protein that interacts with thioredoxin at its redox-active cysteine residues (15). Since the thioredoxin/Txnip interaction occurs in the cytoplasm, we assume that it interacts only with thioredoxin-1. However, thioredoxin-2, the mitochondrial isoform of thioredoxin, also has the typical cysteine-containing motif, which potentially would allow the interaction with Txnip (30). Since no data are known regarding mitochondrial localization of Txnip, we can only speculate whether this interaction can occur in living cells.

Our results demonstrate the inhibition of thioredoxin activity in hyperglycemia, which can be explained by the specific induction of Txnip, the endogenous inhibitor of thioredoxin. Hyperglycemia enhances the thioredoxin/Txnip interaction leading to a functional inhibition of antioxidative thioredoxin function. This specific interaction results in a shift of the cellular redox balance that promotes increased intracellular oxidative stress. While previous reports described an increased formation of ROS (9, 10), our findings demonstrate the functional inhibition of a central ROS-reducing cellular system in diabetes mellitus.

A pivotal mechanism leading to oxidative stress in hyperglycemia is the increased formation of superoxide anion by the mitochondria (9). Superoxide anion activates several major pathways of cellular damage in hyperglycemia: the polyol pathway, increased flux through the hexosamine pathway, activation of PKC, and the formation of advanced glycation end products (3, 9). Increased mitochondrial formation of superoxide anion has been attributed to increased glycolytic production of pyruvate and NADH that in turn leads to an increase of the mitochondrial proton gradient with excess production of superoxide anion (3). It can be prevented by overexpression of uncoupling protein-1 (UCP-1) leading to a breakdown of the proton gradient or overexpression of superoxide dismutase leading to increased degradation of superoxide anion (9). The activation of PKC plays a role in the activation of the membrane-bound NADPH oxidase resulting in further increase of superoxide production (10). Superoxide anion is also known to interact with nitric oxide (NO) producing the highly reactive metabolite peroxynitrate that in turn leads to uncoupling of endothelial NO synthase (31). Furthermore, uncoupling of NO synthase also occurs when this enzyme is deprived of its critical co-factor tetrahydrobiopterin or the substrate L-arginine. Uncoupling of endothelial NO synthase results in the production of molecular oxygen at the prosthetic heme site rather than formation of NO (31, 32).

Based on the experimental results of the present study, additional mechanisms might also contribute to increased levels of hydrogen peroxide in hyperglycemia. Gene silencing of Txnip prevented reduction of thioredoxin activity and reduces intracellular levels of ROS in hyperglycemia. Notably, adenoviral overexpression of thioredoxin reduces hyperglycemia-induced levels of ROS, while overexpression of Txnip enhances oxidative stress. Gene knockdown of Txnip reduced the hyperglycemia-induced increase in oxidative stress compared with controls without significant differences at base line. However, hyperglycemia still increases levels of hydrogen peroxide in cells transfected with Txnip RNAi as measured by the cell-permeable and redox-sensitive compound DCFDA that interacts rather specifically with hydrogen peroxide. This increase might reflect levels of reactive oxygen species that overwhelm the scavenging capacity of the thioredoxin system even in the absence of the endogenous inhibitor Txnip. Notably, superoxide dismustase, glutathione peroxidase, and catalase, all central enzymes in the antioxidative defense mechanisms of the cell, are induced under hyperglycemic conditions, most probably reflecting a counter-regulatory mechanism of the cell (33). In addition, increased levels of hydrogen peroxide that result from impaired scavenging by thioredoxin are known to inhibit the Cu,Zn-superoxide dismutase activity (34) and activate NADPH oxidase (35). These mechanisms could in turn lead to an ambient increase of superoxide anion. Therefore, the induction of Txnip in hyperglycemia represents a unique molecular switch mechanism that results in a reduced scavenging capacity of the antioxidative thioredoxin system leading to increased oxidative stress.

The PI 3-kinase/Akt pathway negatively regulates the transcriptional activation of Txnip, while activation of p38 MAPK represents a necessary step in the increased expression of Txnip in hyperglycemia. Hyperglycemia inhibits activation of Akt; however, we can only speculate about the potential mechanisms of reduced activity of the PI 3-kinase/Akt pathway in hyperglycemia. One possible candidate for reduced Akt activity in hyperglycemia is the mammalian homolog of Drosophila tribbles, which functions as a negative modulator of Akt (36). By directly binding to Akt, TRB3 blocks the activation of this kinase.

The induction of Txnip in hyperglycemia is not restricted to vascular tissue. Through transcriptional screening of glucose-induced gene expression, Txnip has been identified as one of the genes with the highest induction in response to glucose incubation in fibroblasts (37), islet cells (38), and mesangial cells (39). Moreover, increased renal expression of Txnip was demonstrated recently in an animal model of STZ-induced diabetes mellitus (39). The induction of Txnip by glucose seems to be a sustained effect and can be detected up to 36 h after stimulation in mesangial cells (39). Our experimental findings suggest a direct and concentration-dependent regulation of Txnip by glucose in hyperglycemia. In addition to its ROS promoting effects leading to oxidative stress, Txnip may also play a crucial role in reducing cellular viability in hyperglycemia by sensitizing cell toward apoptosis (13). Therefore, this recently discovered gene product may have diverse effects with broad pathophysiological implications in the development of end-organ damage in diabetes mellitus.


   FOOTNOTES
 
* This work was supported by grants from the NHLBI, National Institutes of Health, the Deutsche Akademie der Naturforscher Leopoldina (to P. C. S.), and the Banyu-Merck Fellowship in Cardiovascular Medicine (to T. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Cardiovascular Division, Brigham and Women's Hospital, 65 Landsdowne St., Cambridge, MA 02139. Tel.: 617-768-8272; Fax: 617-768-8270; E-mail: rlee{at}rics.bwh.harvard.edu.

1 The abbreviations used are: ROS, reactive oxygen species; Txnip, thioredoxin-interacting protein; SMC, smooth muscle cell; PDGF, platelet-derived growth factor; MAPK, mitogen-activated protein kinase; RNAi, small interfering RNA; DCFDA, 2',7'-dichlorodihydrofluorecein diacetate; DHE, dihydroethidium bromide; STZ, streptozotocin; Ad, adenovirus; GFP, green fluorescent protein; PI, phosphatidylinositol; PKC, protein kinase C; Trx, thioredoxin. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rosen, P., Nawroth, P. P., King, G., Moller, W., Tritschler, H. J., and Packer, L. (2001) Diabetes Metab. Res. Rev. 17, 189–212[CrossRef][Medline] [Order article via Infotrieve]
  2. Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J., Jr., Chow, W. S., Stern, D., and Schmidt, A. M. (1998) Nat. Med. 4, 1025–1031[CrossRef][Medline] [Order article via Infotrieve]
  3. Brownlee, M. (2001) Nature 414, 813–820[CrossRef][Medline] [Order article via Infotrieve]
  4. Suh, Y. A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., and Lambeth, J. D. (1999) Nature 401, 79–82[CrossRef][Medline] [Order article via Infotrieve]
  5. Griendling, K. K., Sorescu, D., Lassegue, B., and Ushio-Fukai, M. (2002) Arterioscler. Thromb. Vasc. Biol. 20, 2175–2183
  6. Sundaresan, M., Yu, Z. X., Ferrans, V. J., Irani, K., and Finkel, T. (1995) Science 270, 296–299[Abstract/Free Full Text]
  7. Prieto-Alamo, M. J., Jurado, J., Gallardo-Madueno, R., Monje-Casas, F., Holmgren, A., and Pueyo, C. (2000) J. Biol. Chem. 275, 13398–13405[Abstract/Free Full Text]
  8. Nordberg, J., and Arner, E. S. (2001) Free Radic. Biol. Med. 31, 1287–1312[CrossRef][Medline] [Order article via Infotrieve]
  9. Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H. P., Giardino, I., and Brownlee, M. (2000) Nature 404, 787–790[CrossRef][Medline] [Order article via Infotrieve]
  10. Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., Sano, H., Utsumi, H., and Nawata, H. (2000) Diabetes 49, 1939–1945[Abstract]
  11. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237–271[CrossRef][Medline] [Order article via Infotrieve]
  12. Griendling, K. K., and Alexander, R. W. (1997) Circulation 96, 3264–3265
  13. Wang, Y., De Keulenaer, G. W., and Lee, R. T. (2002) J. Biol. Chem. 277, 26496–26500[Abstract/Free Full Text]
  14. Schulze, P. C., De Keulenaer, G. W., Yoshioka, J., Kassik, K. A., and Lee, R. T. (2002) Circ. Res. 91, 689–695[Abstract/Free Full Text]
  15. Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y., and Yodoi, J. (1999) J. Biol. Chem. 274, 21645–21650[Abstract/Free Full Text]
  16. Junn, E., Han, S. H., Im, J. Y., Yang, Y., Cho, E. W., Um, H. D., Kim, D. K., Lee, K. W., Han, P. L., Rhee, S. G., and Choi, I. (2000) J. Immunol. 164, 6287–6295[Abstract/Free Full Text]
  17. Way, K. J., Katai, N., and King, G. L. (2001) Diabet. Med. 18, 945–959[CrossRef][Medline] [Order article via Infotrieve]
  18. Federici, M., Menghini, R., Mauriello, A., Hribal, M. L., Ferrelli, F., Lauro, D., Sbraccia, P., Spagnoli, L. G., Sesti, G., and Lauro, R. (2002) Circulation 106, 466–472[Abstract/Free Full Text]
  19. Zhao, H., Kalivendi, S., Zhang, H., Joseph, J., Nithipatikom, K., Vasquez-Vivar, J., and Kalyanaraman, B. (2003) Free Radic. Biol. Med. 34, 1359–1368[CrossRef][Medline] [Order article via Infotrieve]
  20. Szöcs, K., Lassegue, B., Sorescu, D., Hilenski, L. L., Valppu, L., Couse, T. L., Wolcox, J. N., Quinn, M. T., Lambeth, J. D., and Griendling, K. K. (2002) Arterioscler. Thromb. Vasc. Biol. 22, 21–27[Abstract/Free Full Text]
  21. Munzel, T., Afanas'ev, I. B., Kleschyov, A. L., and Harrison, D. G. (2002) Arterioscler. Thromb. Vasc. Biol. 22, 1761–1768[Abstract/Free Full Text]
  22. Matsui, M., Oshima, M., Oshima, H., Takaku, K., Maruyama, T., Yodoi, J., and Taketo, M. M. (1996) Dev. Biol. 178, 179–185[CrossRef][Medline] [Order article via Infotrieve]
  23. Kanzok, S. M., Fechner, A., Bauer, H., Ulschmid, J. K., Muller, H. M., Botella-Munoz, J., Schneuwly, S., Schirmer, R., and Becker, K. (2001) Science 291, 643–646[Abstract/Free Full Text]
  24. Haendeler, J., Hoffmann, J., Tischler, V., Berk, B. C., Zeiher, A. M., and Dimmeler, S. (2002) Nat. Cell Biol. 4, 743–749[CrossRef][Medline] [Order article via Infotrieve]
  25. Schenk, H., Klein, M., Erdbrügger, W., Dröge, W., and Schulze-Osthoff, K. (1994) Proc. Nat. Acad. Sci. U. S. A. 91, 1672–1676[Abstract/Free Full Text]
  26. Hirota, K., Murata, M., Sachi, Y., Nakamura, H., Takeuchi, J., Mori, K., and Yodoi, J. (1999) J. Biol. Chem. 274, 27891–27897[Abstract/Free Full Text]
  27. Pekkari, K., Avila-Carino, J., Gurunath, R., Bengtsson, A., Scheynius, A., and Holmgren, A. (2003) FEBS Lett. 539, 143–148[CrossRef][Medline] [Order article via Infotrieve]
  28. Tanudji, M., Hevi, S., and Chuck, S. L. (2003) Am. J. Physiol. Cell Physiol. 284, C1272–C1279[Abstract/Free Full Text]
  29. Liu, Y., and Min, W. (2002) Circ. Res. 90, 1259–1266[Abstract/Free Full Text]
  30. Spyrou, G., Enmark, E., Miranda-Vizuete, A., and Gustafsson, J. (1997) J. Biol. Chem. 272, 2936–2941[Abstract/Free Full Text]
  31. Zou, M. H., Shi, C., and Cohen, R. A. (2002) J. Clin. Invest. 109, 817–826[CrossRef][Medline] [Order article via Infotrieve]
  32. Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., and Harrison, D. G. (2003) J. Clin. Invest. 111, 1201–1209[CrossRef][Medline] [Order article via Infotrieve]
  33. Ceriello, A., dello Russo, P., Amstad, P., and Cerutti, P. (1996) Diabetes 45, 471–477[Abstract]
  34. Hink, H. U., Santanam, N., Dikalov, S., McCann, L., Nguyen, A. D., Parthasarathy, S., Harrison, D. G., and Fukai, T. (2002) Arterioscler. Thromb. Vasc. Biol. 22, 1402–1408[Abstract/Free Full Text]
  35. Li, W. G., Miller, F. J., Jr., Zhang, H. J., Spitz, D. R., Oberley, L. W., and Weintraub, N. L. (2001) J. Biol. Chem. 276, 29251–29256[Abstract/Free Full Text]
  36. Du, K., Herzig, S., Kulkarni, R. N., and Montminy, M. (2003) Science 300, 1574–1577[Abstract/Free Full Text]
  37. Hirota, T., Okano, T., Kokame, K., Shirotani-Ikejima, H., Miyata, T., and Fukada, Y. (2002) J. Biol. Chem. 277, 44244–44251[Abstract/Free Full Text]
  38. Shalev, A., Pise-Masison, C. A., Radonovich, M., Hoffmann, S. C., Hirshberg, B., Brady, J. N., and Harlan, D. M. (2002) Endocrinology 143, 3695–3698[Abstract]
  39. Kobayashi, T., Uehara, S., Ikeda, T., Itadani, H., and Kotani, H. (2003) Kidney Int. 64, 1632–1642[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
C. Gerhardinger, Z. Dagher, P. Sebastiani, Y. S. Park, and M. Lorenzi
The Transforming Growth Factor-{beta} Pathway Is a Common Target of Drugs That Prevent Experimental Diabetic Retinopathy
Diabetes, July 1, 2009; 58(7): 1659 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
F.-X. Yu, S.-R. Goh, R.-P. Dai, and Y. Luo
Adenosine-Containing Molecules Amplify Glucose Signaling and Enhance Txnip Expression
Mol. Endocrinol., June 1, 2009; 23(6): 932 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. Masson, S. Koren, F. Razik, H. Goldberg, E. P. Kwan, L. Sheu, H. Y. Gaisano, and I. G. Fantus
High {beta}-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice
Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1251 - E1261.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Chen, H. Cha-Molstad, A. Szabo, and A. Shalev
Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein
Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1133 - E1139.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Advani, R. E. Gilbert, K. Thai, R. M. Gow, R. G. Langham, A. J. Cox, K. A. Connelly, Y. Zhang, A. M. Herzenberg, P. K. Christensen, et al.
Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 730 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S.-T. Pang, W.-C. Hsieh, C.-K. Chuang, C.-H. Chao, W.-H. Weng, and H.-H. Juang
Thioredoxin-interacting protein: an oxidative stress-related gene is upregulated by glucose in human prostate carcinoma cells
J. Mol. Endocrinol., March 1, 2009; 42(3): 205 - 214.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S.-i. Oka, E. Yoshihara, A. Bizen-Abe, W. Liu, M. Watanabe, J. Yodoi, and H. Masutani
Thioredoxin Binding Protein-2/Thioredoxin-Interacting Protein Is a Critical Regulator of Insulin Secretion and Peroxisome Proliferator-Activated Receptor Function
Endocrinology, March 1, 2009; 150(3): 1225 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
Z. Lappalainen, J. Lappalainen, N. K. J. Oksala, D. E. Laaksonen, S. Khanna, C. K. Sen, and M. Atalay
Diabetes impairs exercise training-associated thioredoxin response and glutathione status in rat brain
J Appl Physiol, February 1, 2009; 106(2): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-L. Chen, C.-F. Lin, W.-T. Chang, W.-C. Huang, C.-F. Teng, and Y.-S. Lin
Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway
Blood, April 15, 2008; 111(8): 4365 - 4374.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Chen, G. Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev
Thioredoxin-Interacting Protein: A Critical Link Between Glucose Toxicity and {beta}-Cell Apoptosis
Diabetes, April 1, 2008; 57(4): 938 - 944.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. C. Berk
Atheroprotective Signaling Mechanisms Activated by Steady Laminar Flow in Endothelial Cells
Circulation, February 26, 2008; 117(8): 1082 - 1089.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. A. Chutkow, P. Patwari, J. Yoshioka, and R. T. Lee
Thioredoxin-interacting Protein (Txnip) Is a Critical Regulator of Hepatic Glucose Production
J. Biol. Chem., January 25, 2008; 283(4): 2397 - 2406.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. A. Davis
Searching for Causality of Knocking Out Txnip: Is Txnip Missing in Action?
Circ. Res., December 7, 2007; 101(12): 1216 - 1218.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Yoshioka, K. Imahashi, S. A. Gabel, W. A. Chutkow, A. A. Burds, J. Gannon, P. C. Schulze, C. MacGillivray, R. E. London, E. Murphy, et al.
Targeted Deletion of Thioredoxin-Interacting Protein Regulates Cardiac Dysfunction in Response to Pressure Overload
Circ. Res., December 7, 2007; 101(12): 1328 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. Qi, X. Chen, R. E. Gilbert, Y. Zhang, M. Waltham, M. Schache, D. J. Kelly, and C. A. Pollock
High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-{beta}1
Am. J. Pathol., September 1, 2007; 171(3): 744 - 754.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Turturro, G. Von Burton, and E. Friday
Hyperglycemia-Induced Thioredoxin-Interacting Protein Expression Differs in Breast Cancer-Derived Cells and Regulates Paclitaxel IC50
Clin. Cancer Res., June 15, 2007; 13(12): 3724 - 3730.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Hamada, S. Miyata, T. Nii-Kono, R. Kitazawa, S. Kitazawa, S. Higo, M. Fukunaga, S. Ueyama, H. Nakamura, J. Yodoi, et al.
Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1547 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. J. E. Tissing, M. L. den Boer, J. P. P. Meijerink, R. X. Menezes, S. Swagemakers, P. J. van der Spek, S. E. Sallan, S. A. Armstrong, and R. Pieters
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells
Blood, May 1, 2007; 109(9): 3929 - 3935.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Berndt, C. H. Lillig, and A. Holmgren
Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1227 - H1236.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
I. C Greenman, E. Gomez, C. E J Moore, and T. P Herbert
Distinct glucose-dependent stress responses revealed by translational profiling in pancreatic {beta}-cells
J. Endocrinol., January 1, 2007; 192(1): 179 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Liang and J. L. Pietrusz
Thiol-Related Genes in Diabetic Complications: A Novel Protective Role for Endogenous Thioredoxin 2
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 77 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. C. Schulze, H. Liu, E. Choe, J. Yoshioka, A. Shalev, K. D. Bloch, and R. T. Lee
Nitric Oxide-Dependent Suppression of Thioredoxin-Interacting Protein Expression Enhances Thioredoxin Activity
Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2666 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
G.-H. Liu, J. Qu, and X. Shen
Thioredoxin-mediated Negative Autoregulation of Peroxisome Proliferator-activated Receptor {alpha} Transcriptional Activity
Mol. Biol. Cell, April 1, 2006; 17(4): 1822 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Kolbe, A. Tiessen, H. Schluepmann, M. Paul, S. Ulrich, and P. Geigenberger
Trehalose 6-phosphate regulates starch synthesis via posttranslational redox activation of ADP-glucose pyrophosphorylase
PNAS, August 2, 2005; 102(31): 11118 - 11123.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. Song, J. L. Barth, Y. Yu, K. Lu, A. Dashti, Y. Huang, C. K. Gittinger, W. S. Argraves, and T. J. Lyons
Effects of Oxidized and Glycated LDL on Gene Expression in Human Retinal Capillary Pericytes
Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2974 - 2982.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
R. A. Currie, V. Bombail, J. D. Oliver, D. J. Moore, F. L. Lim, V. Gwilliam, I. Kimber, K. Chipman, J. G. Moggs, and G. Orphanides
Gene Ontology Mapping as an Unbiased Method for Identifying Molecular Pathways and Processes Affected by Toxicant Exposure: Application to Acute Effects Caused by the Rodent Non-Genotoxic Carcinogen Diethylhexylphthalate
Toxicol. Sci., August 1, 2005; 86(2): 453 - 469.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. H. Minn, C. Hafele, and A. Shalev
Thioredoxin-Interacting Protein Is Stimulated by Glucose through a Carbohydrate Response Element and Induces {beta}-Cell Apoptosis
Endocrinology, May 1, 2005; 146(5): 2397 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. S. Sheth, L. W. Castellani, S. Chari, C. Wagg, C. K. Thipphavong, J. S. Bodnar, P. Tontonoz, A. D. Attie, G. D. Lopaschuk, and A. J. Lusis
Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition
J. Lipid Res., January 1, 2005; 46(1): 123 - 134.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/29/30369    most recent
M400549200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schulze, P. C.
Right arrow Articles by Lee, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulze, P. C.
Right arrow Articles by Lee, R. T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement